383
Participants
Start Date
November 8, 2022
Primary Completion Date
November 22, 2024
Study Completion Date
November 22, 2024
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
BNT162b4 5 µg
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
BNT162b4 10 µg
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
BNT162b4 15 µg
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
BNT162b4 30 µg
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
BNT162b2 Monovalent (OMI XBB.1.5) 30 µg
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Finger Lakes Clinical Research, Rochester
Cenexel RCA (Research Centers of America), Hollywood
Research Institute of South Florida, Inc., Miami
Alliance for Multispecialty Research, LLC, Knoxville
University of Kentucky Center for Clinical and Translational Science (outpatient clinic), Lexington
CTI Clinical Research Center, Cincinnati
Great Lakes Clinical Trials LLC - Andersonville, Chicago
Alliance for Multispecialty Research, LLC (Kansas), Kansas City
Johnson County Clin-Trials, Inc. (JCCT), Lenexa
DM Clinical Research, Tomball
Clinical Trials of Texas, LLC / Flourish Research, San Antonio
Endeavor Clinical Trials, LLC, San Antonio
Alliance for Multispecialty Research, LLC, Tempe
California Research Foundation, San Diego
Hoag Hospital, Newport Beach
Diablo Clinical Research, Inc., Walnut Creek
Clinical Research Consulting, LLC, Milford
Lead Sponsor
Collaborators (1)
Pfizer
INDUSTRY
BioNTech SE
INDUSTRY